Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA LLC
Published Date: 2/4/2026
Notice
Summary
Sterling Pharma USA LLC wants to become a big-time maker of some powerful controlled substances like psilocybin and DMT for research and early drug testing. People already registered or interested can share their thoughts or ask for a hearing by April 6, 2026. This move could speed up new medicine studies, but only for research—not for regular sales.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Bulk Supplier for Schedule I Research
On January 9, 2026, Sterling Pharma USA LLC applied to be registered as a bulk manufacturer of the Schedule I substances tetrahydrocannabinols (code 7370), 5‑methoxy‑N‑N‑dimethyltryptamine (code 7431), dimethyltryptamine (code 7435), psilocybin (code 7437), and psilocyn (code 7438). If registered, the company may manufacture these substances in bulk to support its internal research and to sell to customers for pre‑clinical trial studies; no other activities for these drug codes would be authorized under the registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in